A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.

doi:10.1158/1078-0432.CCR-19-2409

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2020

Arena Sabrina, Corti Giorgio, Durinikova Erika, Montone Monica, Reilly Nicole M, Russo Mariangela, Lorenzato Annalisa, Arcella Pamela, Lazzari Luca, Rospo Giuseppe, Pagani Massimiliano, Cancelliere Carlotta, Negrino Carola, Isella Claudio, Bartolini Alice, Cassingena Andrea, Amatu Alessio, Mauri Gianluca, Sartore-Bianchi Andrea, Mittica Gloria, Medico Enzo, Marsoni Silvia, Linnebacher Michael, Abrignani Sergio, Siena Salvatore, Di Nicolantonio Federica, Bardelli Alberto

Abstract excerpt

PURPOSE: Defects in the homologous recombination (HR) repair pathway are of clinical interest due to sensitivity of HR-deficient cells to PARP inhibitors. We were interested in defining PARP vulnerability in patients with metastatic colorectal cancer (mCRC) carrying KRAS and BRAF mutations who display poor prognosis, have limited therapeutic options, and represent an unmet clinical need. EXPERIMENTAL DESIGN: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mice, Inbred NOD

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, SCID

Share to Oxaliplatin

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Recombinational DNA Repair

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed

Identifiers

PMID: 31831554
DOI: 10.1158/1078-0432.CCR-19-2409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.PMID 31831554Read ↗

Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP InhibitorsSemantic proximity Read ↗

Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.Semantic proximity Read ↗

PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cellsSemantic proximity Read ↗

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibitionSemantic proximity Read ↗

Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical responseSemantic proximity Read ↗

Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responsesSemantic proximity Read ↗

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.Semantic proximity Read ↗

Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolutionSemantic proximity Read ↗

Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins.Semantic proximity Read ↗

Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal CancerSemantic proximity Read ↗

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.Semantic proximity Read ↗

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor OlaparibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.